Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Department of respiration, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Front Immunol. 2024 Aug 9;15:1379480. doi: 10.3389/fimmu.2024.1379480. eCollection 2024.
Idiopathic pulmonary fibrosis (IPF) is a lethal lung disease characterized by progressive fibrosis, leading to impaired gas exchange and high mortality. The etiology of IPF is complex, with potential links to autoimmune disorders such as hypothyroidism. This study explores the relationship between hypothyroidism and IPF, focusing on the mediating role of plasma proteins.
A two-sample Mendelian randomization (MR) approach was employed to determine the impact of hypothyroidism on IPF and the mediating role of 4,907 plasma proteins, all in individuals of European ancestry. Sensitivity analyses, external validation, and reverse causality tests were conducted to ensure the robustness of the findings. Additionally, the function of causal SNPs was evaluated through gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses.
The findings suggest that hypothyroidism, through altered plasma protein expression, particularly CXCL10, may contribute to the pathogenesis of IPF. This novel insight highlights the potential of CXCL10 as a therapeutic target in IPF, especially in patients with hypothyroidism. The study emphasizes the need for further research into the complex interplay between autoimmune disorders and IPF, with a view towards developing targeted interventions for IPF management.
特发性肺纤维化(IPF)是一种致命的肺部疾病,其特征是进行性纤维化,导致气体交换受损和高死亡率。IPF 的病因复杂,可能与自身免疫性疾病如甲状腺功能减退有关。本研究探讨了甲状腺功能减退与 IPF 之间的关系,重点研究了血浆蛋白的中介作用。
采用两样本 Mendelian 随机化(MR)方法,确定甲状腺功能减退对 IPF 的影响以及 4907 种血浆蛋白的中介作用,所有这些都在欧洲血统个体中进行。进行敏感性分析、外部验证和反向因果关系测试,以确保研究结果的稳健性。此外,还通过基因本体(GO)和京都基因与基因组百科全书(KEGG)通路富集分析评估了因果 SNP 的功能。
研究结果表明,甲状腺功能减退通过改变血浆蛋白表达,特别是 CXCL10,可能导致 IPF 的发病机制。这一新的见解突出了 CXCL10 作为 IPF 治疗靶点的潜力,特别是在甲状腺功能减退的患者中。该研究强调了需要进一步研究自身免疫性疾病与 IPF 之间的复杂相互作用,以期开发针对 IPF 管理的靶向干预措施。